

# Elena Criscuolo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7269340/publications.pdf>

Version: 2024-02-01

36  
papers

1,172  
citations

471061

17  
h-index

433756

31  
g-index

45  
all docs

45  
docs citations

45  
times ranked

2421  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | The interferon landscape along the respiratory tract impacts the severity of COVID-19. <i>Cell</i> , 2021, 184, 4953-4968.e16.   | 13.5 | 165       |
| 2  | Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro. <i>Pharmacological Research</i> , 2021, 163, 105255.  | 3.1  | 88        |
| 3  | Viral Respiratory Pathogens and Lung Injury. <i>Clinical Microbiology Reviews</i> , 2021, 34, .  | 5.7  | 76        |
| 4  | Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials. <i>Emerging Microbes and Infections</i> , 2021, 10, 206-209.  | 3.0  | 74        |
| 5  | Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines. <i>Journal of Immunology Research</i> , 2019, 2019, 1-13.   | 0.9  | 72        |
| 6  | Interferon- $\beta$ Inhibition of Severe Acute Respiratory Syndromeâ€“Coronavirus 2 In Vitro When Administered After Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 222, 722-725.  | 1.9  | 61        |
| 7  | COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. <i>Molecular Therapy</i> , 2022, 30, 311-326.  | 3.7  | 54        |
| 8  | Weak correlation between antibody titers and neutralizing activity in sera from SARSâ€“CoVâ€“2 infected subjects. <i>Journal of Medical Virology</i> , 2021, 93, 2160-2167.  | 2.5  | 52        |
| 9  | Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. <i>PLoS Pathogens</i> , 2021, 17, e1009878.   | 2.1  | 52        |
| 10 | Unconventional CD147â€“dependent platelet activation elicited by SARSâ€“CoVâ€“2 in COVIDâ€“19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 434-448.   | 1.9  | 50        |
| 11 | Bacteriophages and Their Immunological Applications against Infectious Threats. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.  | 0.9  | 47        |
| 12 | Circulating SARS-CoV-2 variants in Italy, October 2020â€“March 2021. <i>Virology Journal</i> , 2021, 18, 168.  | 1.4  | 36        |
| 13 | Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects. <i>Clinica Chimica Acta</i> , 2021, 522, 144-151.   | 0.5  | 28        |
| 14 | Neutralization Interfering Antibodies: A â€œNovelâ€“ Example of Humoral Immune Dysfunction Facilitating Viral Escape?. <i>Viruses</i> , 2012, 4, 1731-1752.  | 1.5  | 26        |
| 15 | Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-12. | 3.3  | 26        |
| 16 | Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine. <i>Vaccines</i> , 2021, 9, 1357.  | 2.1  | 24        |
| 17 | Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects. <i>Journal of Virology</i> , 2019, 93, .  | 1.5  | 21        |
| 18 | Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. <i>Frontiers in Microbiology</i> , 2020, 11, 1704.  | 1.5  | 18        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11.  | 3.3 | 16        |
| 20 | Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes. <i>Drug Discovery Today</i> , 2016, 21, 682-691.         | 3.2 | 16        |
| 21 | Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy. <i>Antiviral Research</i> , 2014, 108, 94-103. | 1.9 | 13        |
| 22 | IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e829-e831.  | 2.2 | 13        |
| 23 | Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. <i>New Microbiologica</i> , 2012, 35, 399-406.   | 0.1 | 13        |
| 24 | Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases. <i>Vaccines</i> , 2022, 10, 801.                        | 2.1 | 13        |
| 25 | Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. <i>Viruses</i> , 2021, 13, 1514.   | 1.5 | 12        |
| 26 | Nanopore ReCappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs. <i>Nucleic Acids Research</i> , 2022, 50, 3475-3489.   | 6.5 | 12        |
| 27 | Role and potential therapeutic use of antibodies against herpetic infections. <i>Clinical Microbiology and Infection</i> , 2017, 23, 381-386.  | 2.8 | 11        |
| 28 | Next Generation Vaccines for Infectious Diseases. <i>Journal of Immunology Research</i> , 2019, 2019, 1-2.   | 0.9 | 11        |
| 29 | Influenza B-Cells Protective Epitope Characterization: A Passkey for the Rational Design of New Broad-Range Anti-Influenza Vaccines. <i>Viruses</i> , 2012, 4, 3090-3108.  | 1.5 | 10        |
| 30 | A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 6140-6156.                  | 1.9 | 10        |
| 31 | Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge. <i>Antiviral Research</i> , 2017, 143, 48-61.  | 1.9 | 9         |
| 32 | Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle. <i>Antiviral Research</i> , 2018, 151, 71-77.  | 1.9 | 9         |
| 33 | Epitope Mapping by Epitope Excision, Hydrogen/Deuterium Exchange, and Peptide-Panning Techniques Combined with In Silico Analysis. <i>Methods in Molecular Biology</i> , 2014, 1131, 427-446.                                | 0.4 | 7         |
| 34 | Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols. <i>Virology Journal</i> , 2020, 17, 103.  | 1.4 | 4         |
| 35 | Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1232.  | 1.5 | 2         |
| 36 | Phage Therapy: An Alternative to Antibiotics. , 2020, , 335-346.   |     | 0         |